AR116315A1 - Compuestos de triazolo-pirimidina y usos de los mismos - Google Patents
Compuestos de triazolo-pirimidina y usos de los mismosInfo
- Publication number
- AR116315A1 AR116315A1 ARP190102589A ARP190102589A AR116315A1 AR 116315 A1 AR116315 A1 AR 116315A1 AR P190102589 A ARP190102589 A AR P190102589A AR P190102589 A ARP190102589 A AR P190102589A AR 116315 A1 AR116315 A1 AR 116315A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- amino
- unsaturated
- membered saturated
- carbamoyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Virology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018105220 | 2018-09-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR116315A1 true AR116315A1 (es) | 2021-04-21 |
Family
ID=69778192
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190102589A AR116315A1 (es) | 2018-09-12 | 2019-09-11 | Compuestos de triazolo-pirimidina y usos de los mismos |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10858365B2 (enExample) |
| EP (1) | EP3849983A4 (enExample) |
| JP (2) | JP7572353B2 (enExample) |
| KR (1) | KR102841843B1 (enExample) |
| CN (3) | CN111601809A (enExample) |
| AR (1) | AR116315A1 (enExample) |
| AU (1) | AU2019340767B9 (enExample) |
| BR (1) | BR112021004774A2 (enExample) |
| CA (1) | CA3111869A1 (enExample) |
| MX (1) | MX2021002998A (enExample) |
| TW (1) | TWI820209B (enExample) |
| WO (1) | WO2020052631A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3600328A4 (en) * | 2017-03-24 | 2021-01-06 | 3100 Central Expressway LLC | MERGED TRIAZOLO-PYRIMIDINE COMPOUNDS WITH USEFUL PHARMACEUTICAL APPLICATION |
| JP2020527588A (ja) | 2017-07-18 | 2020-09-10 | ニューベイション・バイオ・インコーポレイテッドＮｕｖａｔｉｏｎ Ｂｉｏ Ｉｎｃ． | アデノシンアンタゴニストとしてのヘテロ環式化合物 |
| AU2019227607C1 (en) * | 2018-02-27 | 2023-07-20 | Incyte Corporation | Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors |
| US11220510B2 (en) | 2018-04-09 | 2022-01-11 | Incyte Corporation | Pyrrole tricyclic compounds as A2A / A2B inhibitors |
| EP3810610A1 (en) | 2018-05-18 | 2021-04-28 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
| CN117304191A (zh) | 2018-07-05 | 2023-12-29 | 因赛特公司 | 作为a2a/a2b抑制剂的稠合吡嗪衍生物 |
| AR116315A1 (es) * | 2018-09-12 | 2021-04-21 | Dizal Jiangsu Pharmaceutical Co Ltd | Compuestos de triazolo-pirimidina y usos de los mismos |
| WO2020150674A1 (en) | 2019-01-18 | 2020-07-23 | Nuvation Bio Inc. | Heterocyclic compounds as adenosine antagonists |
| US11254670B2 (en) | 2019-01-18 | 2022-02-22 | Nuvation Bio Inc. | 1,8-naphthyridinone compounds and uses thereof |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| PH12022550470A1 (en) * | 2019-08-26 | 2023-02-27 | Incyte Corp | Triazolopyrimidines as a2a / a2b inhibitors |
| WO2021156439A1 (en) | 2020-02-06 | 2021-08-12 | Astrazeneca Ab | Triazole compounds as adenosine receptor antagonists |
| CN120022278A (zh) * | 2023-11-22 | 2025-05-23 | 英诺湖医药(杭州)有限公司 | 用于治疗癌症的化合物 |
| CN117865963B (zh) * | 2023-12-15 | 2026-02-24 | 上海凌凯科技股份有限公司 | 一种嘧啶酮衍生物的合成方法及嘧啶酮衍生物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998042711A1 (en) * | 1997-03-24 | 1998-10-01 | Kyowa Hakko Kogyo Co., Ltd. | [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVES |
| WO2002079204A1 (en) | 2001-03-28 | 2002-10-10 | Kyowa Hakko Kogyo Co., Ltd. | 8-thiazolyl[1,2,4]triazolo[1,5-c]pyrimidine derivative |
| TW200300686A (en) | 2001-11-30 | 2003-06-16 | Schering Corp | Adenosine A2a receptor antagonists |
| AU2003272886A1 (en) | 2002-09-24 | 2004-04-19 | Kyowa Hakko Kogyo Co., Ltd. | (1,2,4)-TRIAZOLO(1,5-c)PYRIMIDINE DERIVATIVE |
| MX389798B (es) * | 2017-01-20 | 2025-03-20 | Arcus Biosciences Inc | Azolopirimidina para el tratamiento de trastornos relacionados con el cáncer. |
| KR20190129851A (ko) * | 2017-03-16 | 2019-11-20 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 헤테로아릴[4,3-c]피리미딘-5-아민 유도체, 이의 제조 방법 및 이의 의학적 용도 |
| EP3611174B1 (en) * | 2017-04-07 | 2022-06-08 | Medshine Discovery Inc. | [1,2,4]triazolo[1,5-c]pyrimidine derivative as a2a receptor inhibitor |
| CN109535161B (zh) * | 2017-09-22 | 2021-09-03 | 江苏恒瑞医药股份有限公司 | 三唑并嘧啶类衍生物、其制备方法及其在医药上的应用 |
| AU2019227607C1 (en) * | 2018-02-27 | 2023-07-20 | Incyte Corporation | Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors |
| CN112105617B (zh) * | 2018-04-28 | 2022-04-05 | 南京明德新药研发有限公司 | 一种三唑并嘧啶类化合物的晶型、盐型及其制备方法 |
| AR116315A1 (es) * | 2018-09-12 | 2021-04-21 | Dizal Jiangsu Pharmaceutical Co Ltd | Compuestos de triazolo-pirimidina y usos de los mismos |
-
2019
- 2019-09-11 AR ARP190102589A patent/AR116315A1/es unknown
- 2019-09-11 TW TW108132759A patent/TWI820209B/zh active
- 2019-09-12 CN CN201980006436.2A patent/CN111601809A/zh active Pending
- 2019-09-12 JP JP2021513827A patent/JP7572353B2/ja active Active
- 2019-09-12 WO PCT/CN2019/105591 patent/WO2020052631A1/en not_active Ceased
- 2019-09-12 MX MX2021002998A patent/MX2021002998A/es unknown
- 2019-09-12 BR BR112021004774-3A patent/BR112021004774A2/pt unknown
- 2019-09-12 KR KR1020217010809A patent/KR102841843B1/ko active Active
- 2019-09-12 CA CA3111869A patent/CA3111869A1/en active Pending
- 2019-09-12 EP EP19859380.8A patent/EP3849983A4/en active Pending
- 2019-09-12 AU AU2019340767A patent/AU2019340767B9/en active Active
- 2019-09-12 CN CN202010657655.1A patent/CN112279852B/zh active Active
- 2019-09-12 CN CN202010656938.4A patent/CN111635408B/zh active Active
-
2020
- 2020-06-24 US US16/910,334 patent/US10858365B2/en active Active
- 2020-09-22 US US17/027,740 patent/US11629147B2/en active Active
-
2024
- 2024-06-13 JP JP2024096058A patent/JP2024123079A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11629147B2 (en) | 2023-04-18 |
| MX2021002998A (es) | 2021-05-14 |
| JP2022500402A (ja) | 2022-01-04 |
| AU2019340767B9 (en) | 2024-12-05 |
| CN111601809A (zh) | 2020-08-28 |
| TW202024089A (zh) | 2020-07-01 |
| CA3111869A1 (en) | 2020-03-19 |
| US10858365B2 (en) | 2020-12-08 |
| KR102841843B1 (ko) | 2025-08-01 |
| CN112279852B (zh) | 2023-01-17 |
| EP3849983A4 (en) | 2022-06-01 |
| CN111635408B (zh) | 2022-07-22 |
| WO2020052631A1 (en) | 2020-03-19 |
| AU2019340767A1 (en) | 2021-04-08 |
| KR20210075996A (ko) | 2021-06-23 |
| CN112279852A (zh) | 2021-01-29 |
| JP7572353B2 (ja) | 2024-10-23 |
| AU2019340767B2 (en) | 2024-11-14 |
| JP2024123079A (ja) | 2024-09-10 |
| TWI820209B (zh) | 2023-11-01 |
| BR112021004774A2 (pt) | 2021-08-03 |
| CN111635408A (zh) | 2020-09-08 |
| US20200331918A1 (en) | 2020-10-22 |
| EP3849983A1 (en) | 2021-07-21 |
| US20210009600A1 (en) | 2021-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR119018A1 (es) | Inhibidores de proteína quinasas dependientes de adn | |
| AR120080A1 (es) | Compuestos lipídicos de cola ramificada y composiciones para la administración intracelular de agentes terapéuticos | |
| AR127309A2 (es) | Derivados de piridazinona | |
| AR121044A1 (es) | Inhibidores de egfr | |
| AR113964A1 (es) | Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpa | |
| AR120338A1 (es) | Piridazinonas como inhibidores de parp7 | |
| PE20161031A1 (es) | Agentes citotoxicos bifuncionales | |
| AR095464A1 (es) | Compuestos de heteroarilo y usos de los mismos | |
| AR114793A1 (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de los mismos | |
| AR115985A1 (es) | Compuestos de pirazina y usos de los mismos | |
| AR110400A1 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| AR108130A1 (es) | Derivados de pirazolopirimidina | |
| AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. | |
| AR112392A1 (es) | Compuesto tricíclico de pirazol, su uso para fabricar un medicamento y composición farmaceutica que lo comprende | |
| AR109709A1 (es) | Inhibidores de la fosfatidilinositol 3-quinasa | |
| SV2016005328A (es) | Nuevos derivados de pirazolo pirimidina y su uso como inhibidores de malt1 | |
| AR119010A1 (es) | Compuestos, composiciones y métodos de uso | |
| AR051026A1 (es) | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa | |
| UY37133A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| AR079553A1 (es) | Derivados de diaza-espiro-[5,5]-undecanos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos del snc, tales como trastornos del sueno y de la dependencia,entre otros. | |
| AR040047A1 (es) | 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de la 5-hidroxitriptamina-6 | |
| AR118724A1 (es) | Inhibidores de dihidroorotato deshidrogenasa | |
| AR100006A1 (es) | Derivados de tubulisina | |
| AR091534A1 (es) | Derivados de sulfonamida y metodos de uso de los mismos para mejorar la farmacocinetica de un farmaco | |
| AR109711A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa |